About
CAR-T, TILs & CRISPR-Cas9 gene editing
Areas of Focus
Categories
Stem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Clinical Trials (15)
View allTotal Trials
15
As Lead Sponsor
15
As Collaborator
0
Total Enrollment
1,115
By Phase
PHASE1/PHASE2: 15
By Status
RECRUITING: 15
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07066982Lead Sponsor
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
PHASE1/PHASE2Recruiting
60 participants
Started: May 29, 2025 · Completed: Dec 28, 2028
NCT07032129Lead Sponsor
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
PHASE1/PHASE2Recruiting
60 participants
Started: Apr 29, 2025 · Completed: Dec 28, 2028
NCT07066995Lead Sponsor
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
PHASE1/PHASE2Recruiting
60 participants
Started: Apr 29, 2025 · Completed: Dec 28, 2028
NCT07067255Lead Sponsor
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
PHASE1/PHASE2Recruiting
80 participants
Started: Apr 29, 2025 · Completed: Dec 28, 2029
NCT06640582Lead Sponsor
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
PHASE1/PHASE2Recruiting
85 participants
Started: Oct 20, 2024 · Completed: Dec 28, 2026
Locations (1)
Headquarters
Newark, DE, United States
Map
Loading map...